MICROINFLAMMATION IN DN
Inflammation is characterized by inflammatory
cell accrual, increased expression of adhesion molecules, chemokines, and
inflammatory cytokines. These features are seen in DN, though they are quite
mild as compared with classic inflammatory diseases. Therefore, the low grade
inflammation that occurs in DN is termed “microinflammation” to distinguish it
from classic inflammation.
In human DN, there is a glomerular
infiltration of monocytes/macrophages that is not secondary to fibrosis as it
occurs in mild and moderate glomerulosclerosis and recedes as sclerosis progresses
[12]. In addition, tubulo-interstitial damage triggers an inflammatory response
with mononuclear cell infiltration that is strongly related to disease
progression [13]. Studies in experimental diabetes have clarified that
macrophage infiltration occurs at an early stage of the disease and correlates
with renal injury [14-16]. Deletion of genes encoding proteins crucial in
driving renal monocyte recruitment such as the chemokine Monocyte Chemoattractant
Protein-1 (MCP-1/CCL2) and the adhesion molecule InterCellular Adhesion
Molecule-1 (ICAM-1) prevents the development of kidney injury in experimental
diabetes [17, 18]. Moreover, a causal link between macrophages and renal damage
has been recently established by demonstrating that macrophage depletion significantly
reduces albuminuria, kidney macrophage recruitment, and glomerular histological
changes and preserves expression of podocyte proteins, such as nephrin and
podocin, important in maintaining glomerular permselectivity [19].
The mechanism whereby macrophages
contribute to the renal damage in DN remains elusive; however, activated
macrophages are capable of secreting a wide range of potentially cytotoxic
products, including proteolytic enzymes and reactive oxygen species (ROS), as
well as both proinflammatory [Tumor Necrosis Factor-a (TNF-a), Interferon-g (IFN-g), Interleukin-1
(IL-1)] and prosclerotic [Transforming Growth Factor-b1 (TGF-b1)] cytokines that can contribute to renal cell
dysfunction/injury. Consistent with this notion, in vitro studies have shown
that mesangial cell exposure to macrophage-conditioned medium increases expression
of extracellular matrix components [20], such as fibronectin, collagen type IV,
laminin, and Tissue Inhibitor of Metalloproteinases (TIMPS), which inhibits
extracellular matrix degradation. In addition, coculture of macrophages and
mesangial cells leads to a synergistic increase in fibronectin production by
mesangial cells [20]. Studies on cultured podocytes have demonstrated that
podocyte exposure to conditioned medium from activated macrophages causes cell
shrinkage, disorganization of F-actin microfilaments, loss of cell processes,
and downregulation of both nephrin and podocin [21]. The specific factor
secreted by macrophages that is responsible for these alterations is often
undetermined, but the pro-inflammatory cytokines TNF-a and IL-1 appear to play a predominant role. Finally,
the direct physical interaction between monocytes/macrophages and glomerular
cells via the adhesion molecule ICAM-1 [22] can amplify the inflammatory
process by favouring glomerular monocyte infiltration through chemokine secretion
and by enhancing the release of inflammatory cytokines by both cell types.
Besides enhancing renal monocyte
recruitment, diabetes also affects the phenotype of macrophages. Infiltrating
macrophages can polarize towards either pro-inflammatory M1 macrophages that play
a key role in tissue injury or anti-inflammatory M2 macrophages that are important
in tissue repair. In experimental diabetes both subsets of macrophages are
increased in the diabetic kidney, though M1 macrophages appear predominant [19,
23, 24]. In addition, a recent in vitro study has demonstrated that M1, but not
M2, macrophages impair integrity of podocyte exposed to high glucose, leading
to enhanced permeability to albumin [19]. Strategies that increase M2 macrophages
relative to M1 at sites of kidney injury have been proposed for renal
protection [25]. Notably adoptive transfer of M2 macrophages to mice with
streptozotocin (STZ)-induced diabetes has been shown to decrease both renal
macrophage accumulation and kidney damage [26].
Given the important role of
micro-inflammation in the pathogenesis of DN, a large number of inflammatory
mediators have been investigated to assess their potential relevance as
clinical biomarkers and/or molecular targets in DN. These studies have clarified
that some proinflammatory systems not only control infiltration and activation
of inflammatory cells and thus indirectly contribute to the kidney damage, but
they also have direct deleterious effects on resident kidney cells that occur
independently of local monocyte accrual, opening an entirely new scenario in
our understanding of the role of inflammatory processes in DN and in our
possibility to exploit it for clinical purposes (Figure 1). In this review, we
will specifically focus on three of these pro-inflammatory systems: the Tumor Necrosis Factor(TNF)-a/TNF-a
receptor system, the Monocyte Chemoattractant Protein-1/CC-chemokine receptor-2 system, and the Endocannabinoid system (ECS) as
recent studies have highlighted their potential clinical relevance in DN. TNF-a has long been implicated in the pathogenesis
of DN, but recent epidemiological studies suggest that TNF-a receptors may also serve as novel biomarkers of
renal function decline. Convincing preclinical data have demonstrated that
blockade of the MCP-1/CCR2 system is beneficial in experimental diabetes, but phase
I and II trials have only recently provided preliminary evidence of effectiveness
and safety in humans. The ECS has been extensively studied in both obese and
type 2 diabetic patients because of its important metabolic effects, but a
previously unsuspected role of the ECS in DN has been only recently elucidated.
Post Comment
No comments